Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate
Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America Partnership to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars INCHEON, Korea, Sept. 11, 2023 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, [...]









